Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2018 December;153(6) > Giornale Italiano di Dermatologia e Venereologia 2018 December;153(6):872-6

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   Freefree

Giornale Italiano di Dermatologia e Venereologia 2018 December;153(6):872-6

DOI: 10.23736/S0392-0488.18.06143-6

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Calcipotriene plus betamethasone dipropionate in aerosol foam formulation: will this effective treatment for mild-to-moderate psoriasis change clinical practice?

Gian Luigi GIOVENE 1 , Luca GIACOMELLI 2, AIDA (Italian Association of Outpatient Dermatologists) Working Group 

1 Private Practitioner, Perugia, Italy; 2 Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy



The fixed-combination of Cal/BD aerosol foam is now entering the Italian market. This drug was developed with a technology that allows an enhanced penetration of the active ingredients into the skin. This enhanced penetration improves local bioavailability and, consequently, Cal/BD aerosol foam therapy is associated with improved clinical outcomes if compared with other products with the same components. The efficacy and safety of Cal/BD aerosol foam were confirmed both in clinical trials and in “field-practice” studies. This short review discusses current evidence on the Cal/BD aerosol foam combination; some preliminary data collected in the Italian clinical practice will be also presented.


KEY WORDS: Calcipotriene - Betamethasone dipropionate - Aerosol foam

top of page